Neuberger Berman Group
PCVX icon

Neuberger Berman Group’s Vaxcyte PCVX Stock Holding History

Neuberger Berman Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$267K Sell
4,593
-319
-6% -$17.3K ﹤0.01% 2063
2026
Q1 		$285K Buy
4,912
+513
+12% +$27.9K ﹤0.01% 1856
2025
Q4 		$203K Buy
+4,399
New +$197K ﹤0.01% 1951
2025
Q2 		– Sell
-81,727
Closed -$3.09M – 2108
2025
Q1 		$3.09M Sell
81,727
-3,405
-4% -$272K ﹤0.01% 1027
2024
Q4 		$6.97M Buy
85,132
+2,399
+3% +$238K 0.01% 880
2024
Q3 		$9.45M Sell
82,733
-25,359
-23% -$2.29M 0.01% 809
2024
Q2 		$8.16M Buy
108,092
+5,781
+6% +$394K 0.01% 803
2024
Q1 		$6.99M Sell
102,311
-70,023
-41% -$4.85M 0.01% 860
2023
Q4 		$10.8M Buy
172,334
+106,143
+160% +$5.51M ﹤0.01% 892
2023
Q3 		$3.37M Buy
66,191
+1,308
+2% +$64.5K ﹤0.01% 972
2023
Q2 		$3.24M Buy
64,883
+34,658
+115% +$1.64M ﹤0.01% 984
2023
Q1 		$1.13M Buy
30,225
+2,539
+9% +$108K ﹤0.01% 1216
2022
Q4 		$1.33M Buy
+27,686
New +$1.09M ﹤0.01% 1162

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Neuberger Berman Group's PCVX Position: Q2 2026 in Review

Neuberger Berman Group reduced its Vaxcyte (PCVX) stake by 6.5% in Q2 2026, selling an estimated $17.3K and leaving 4,593 shares worth $267K. The position accounts for ﹤0.01% of the portfolio, ranked #2063.

Neuberger Berman Group first reported a position in PCVX in Q4 2022 and has held it in 13 quarters since. The position peaked at $10.8M in Q4 2023. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Neuberger Berman Group held 4,593 shares of Vaxcyte worth $267K as of Q2 2026.
  • Neuberger Berman Group sold 319 Vaxcyte shares in Q2 2026, an estimated $17.3K.
  • Vaxcyte made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2063 holding.
  • Neuberger Berman Group first reported a position in Vaxcyte in Q4 2022 and has held it in 13 quarters since.
  • Neuberger Berman Group's Vaxcyte position peaked at $10.8M in Q4 2023.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.